Morgan Stanley has initiated coverage on Danaher Corp (DHR) with an Overweight rating, marking the firm's first assessment of the company. The rating reflects Morgan Stanley's evaluation of Danaher's investment merits, considering its position in the life sciences tools and services industry.
Danaher Corp, headquartered in Washington, D.C., designs, manufactures, and markets a range of products across its Biotechnology, Life Sciences, and Diagnostics segments. The company currently has a market capitalization of $160.2 billion and a P/E ratio of 45.74. As of December 1, 2025, Danaher reported an EPS of 4.86 and a dividend yield of 57.1%.
Upcoming earnings reports are scheduled for April 20, 2026, with an estimated EPS of $2.02 and revenue of $6.1 billion, followed by another report on July 20, 2026, estimating an EPS of $1.98 and revenue of $6.2 billion.
The analyst consensus for Danaher stands at 29 ratings, with 12 Strong Buy, 13 Buy, 4 Hold, and no Sell or Strong Sell ratings, indicating a consensus of Buy. Analyst ratings and price targets provide insights based on research and financial models but should not be the sole basis for investment decisions.
This update provides insight into the firm's current perspective on Danaher Corp as it navigates the competitive landscape of the life sciences sector.